Basic Search
|
Geographic Searches
|
Advanced Search |
Megadeals
Subsidy Tracker Parent Company Summary
Parent Company Name: AstraZeneca
Ownership Structure: publicly traded (ticker symbol LSE: AZN)
Headquartered in: United Kingdom
Major Industry: pharmaceuticals
Specific Industry: pharmaceuticals
| Subsidy Summary | Subsidy Value | Number of Awards |
| State/Local | $428,536,105 | 46 |
| Federal (grants and allocated tax credits) | $24,162,569 | 20 |
| TOTAL | $452,698,674 | 66 |
Loan / Bailout Summary | Total Face Value | Number of Awards |
| State/Local loans, bond financing and venture capital | $0 | 0 |
| Federal loans, loan guarantees and bailout assistance (not including repayments) | $0 | 0 |
| TOTAL | $0 | 0 |
Time Period for State and Local Awards: Earliest year of data: 1996. Availability of data for earlier years varies greatly from program to program. The majority of the listings for this parent company are for the period since 2011.
Time Period for Federal Awards: FY2000 to the present
Notes: Dollar totals do not include awards for which no subsidy value is disclosed.
Links: For a summary of this company's regulatory violations see its Violation Tracker summary page
here.
For an overview of this company's accountability track record, read its Corporate Rap Sheet
here.
For an overview of political contributions associated with this company, see its Follow the Money
page.
| Top 5 States for state/local awards | Total Subsidy $ | Number of Awards |
| Delaware | $178,135,449 | 9 |
| Ohio | $117,000,000 | 6 |
| Connecticut | $102,000,000 | 3 |
| Maryland | $27,895,106 | 23 |
| Massachusetts | $2,705,550 | 3 |
| All other | $800,000 | 2 |
Individual Subsidy Records:
Click on the company name for more information on each subsidy award.
| Company | Location | Subsidy Source | Year | Subsidy Value  | Loan/Bailout Value | Type of Subsidy |
| AstraZeneca | Delaware | multiple | 1999 | $178,000,000 | | MEGADEAL  |
| Amylin Pharmaceuticals | Ohio | multiple | 2007 | $117,000,000 | | MEGADEAL |
| Alexion Pharmaceuticals | Connecticut | state | 2012 | $51,000,000 | | tax credit/rebate |
| Alexion Pharmaceuticals, Inc | Connecticut | state | 2013 | $26,000,000 | | grant/loan hybrid program |
| Alexion Pharmaceuticals, Inc. | Connecticut | state | 2016 | $25,000,000 | | tax credit/rebate |
| MedImmune Inc. | Maryland | state | 2006 | $7,500,000 | | grant/loan hybrid program |
| MEDIMMUNE, LLC | United States | federal | 2018 | $4,893,180 | | federal grant |
| MEDIMMUNE, LLC | United States | federal | 2017 | $4,864,964 | | federal grant |
| AstraZeneca Pharmaceuticals LP | United States | federal | 2012 | $2,713,491 | | federal grant |
| MEDIMMUNE, LLC | United States | federal | 2018 | $2,383,754 | | federal grant |
| AstraZeneca Pharmaceuticals, LP | Maryland | state | 2018 | $2,161,115 | | tax credit/rebate |
| MedImmune, LLC | Maryland | state | 2017 | $1,939,088 | | tax credit/rebate |
| Medimmune, Inc. | Maryland | state | 2007 | $1,570,977 | | tax credit/rebate |
| MedImmune, LLC | Maryland | state | 2016 | $1,553,113 | | tax credit/rebate |
| MedImmune LLC | Maryland | state | 2015 | $1,500,000 | | grant/loan hybrid program |
| Medimmune, LLC | Maryland | state | 2012 | $1,497,096 | | tax credit/rebate |
| Medimmune, LLC | Maryland | state | 2014 | $1,497,096 | | tax credit/rebate |
| MedImmune, LLC | Maryland | state | 2019 | $1,475,043 | | tax credit/rebate |
| ALEXION ANTIBODY TECHNOLOGIES | United States | federal | 2005 | $1,356,000 | | federal grant |
| AstraZeneca Pharmaceuticals, LP | Maryland | state | 2019 | $1,338,392 | | tax credit/rebate |
| MEDIMMUNE, LLC | United States | federal | 2018 | $1,324,736 | | federal grant |
| Medimmune, LLC | Maryland | state | 2015 | $1,264,635 | | tax credit/rebate |
| Synageva BioPharma | Massachusetts | state | 2014 | $1,021,550 | | tax credit/rebate |
| MEDIMMUNE, LLC | United States | federal | 2020 | $936,714 | | federal grant |
| Synageva BioPharma Corp | Massachusetts | state | 2015 | $900,000 | | tax credit/rebate |
| Synageva BioPharma Corp | Massachusetts | state | 2013 | $784,000 | | tax credit/rebate |
| ALEXION PHARMACEUTICALS, INC | United States | federal | 2004 | $737,620 | | federal grant |
| ALEXION PHARMACEUTICALS | United States | federal | 2000 | $732,800 | | federal grant |
| Medimmune, Inc. | Maryland | state | 2005 | $728,623 | | tax credit/rebate |
| Medimmune, LLC | Maryland | state | 2010 | $698,034 | | tax credit/rebate |
| ALEXION PHARMACEUTICALS | United States | federal | 2001 | $647,896 | | federal grant |
| ALEXION PHARMACEUTICALS, INC | United States | federal | 2005 | $627,428 | | federal grant |
| Medimmune, LLC | Maryland | state | 2008 | $611,575 | | tax credit/rebate |
| AstraZeneca Pharmaceuticals LP | Indiana | state | 2017 | $600,000 | | tax credit/rebate |
| ALEXION PHARMACEUTICALS | United States | federal | 2000 | $598,900 | | federal grant |
| AstraZeneca Pharmaceuticals, LP | Maryland | state | 2017 | $534,013 | | tax credit/rebate |
| MedImmune, Inc. | Maryland | local | | $500,000 | | grant/loan hybrid program |
| Medimmune, LLC | Maryland | state | 2009 | $490,223 | | tax credit/rebate |
| Medimmune, LLC | Maryland | state | 2011 | $462,285 | | tax credit/rebate |
| AMYLIN OHIO LLC | Ohio | state | 2009 | $414,661 | | grant |
| ALEXION PHARMACEUTICALS, INC | United States | federal | 2013 | $400,000 | | federal grant |
| ALEXION PHARMACEUTICALS, INC | United States | federal | 2013 | $400,000 | | federal grant |
| ENOBIA PHARMA INC | United States | federal | 2011 | $400,000 | | federal grant |
| MEDIMMUNE VACCINES INC | United States | federal | 2002 | $323,750 | | federal grant |
| ACHILLION PHARMACEUTICALS INC | United States | federal | 2006 | $301,407 | | federal grant |
| ACHILLION PHARMACEUTICALS INC | United States | federal | 2005 | $296,258 | | federal grant |
| Medimmune, Inc. | Maryland | state | 2004 | $294,900 | | tax credit/rebate |
| AstraZeneca Pharmaceuticals LP | Indiana | state | 2017 | $200,000 | | training reimbursement |
| AMYLIN OHIO LLC | Ohio | state | 2013 | $150,000 | | grant |
| MEDIMMUNE VACCINES INC | United States | federal | 2002 | $147,671 | | federal grant |
| AMYLIN OHIO LLC | Ohio | state | 2010 | $138,219 | | grant |
| Medimmune Oncology, Inc. | Maryland | state | 2005 | $111,606 | | tax credit/rebate |
| Medimmune Oncology, Inc. | Maryland | state | 2004 | $103,579 | | tax credit/rebate |
| ALEXION ANTIBODY TECHNOLOGIES | United States | federal | 2005 | $76,000 | | federal grant |
| Astra Zeneca Pharmaceutical | Delaware | state | 2010 | $47,404 | | training reimbursement |
| AMYLIN OHIO LLC | Ohio | state | 2012 | $45,000 | | grant |
| Medimmune Oncology, Inc. | Maryland | state | 2007 | $36,938 | | tax credit/rebate |
| AMYLIN OHIO LLC | Ohio | state | 2010 | $31,792 | | grant |
| MedImmune, Inc. | Maryland | state | 2004 | $26,775 | | training reimbursement |
| Astra Zeneca Pharmaceutical | Delaware | state | 2012 | $20,276 | | training reimbursement |
| Astra Zeneca Pharmaceutical | Delaware | state | 2006 | $16,820 | | training reimbursement |
| Astra Zeneca Pharmaceutical | Delaware | state | 2008 | $16,264 | | training reimbursement |
| Astra Zeneca Pharmaceutical | Delaware | state | 2005 | $14,972 | | training reimbursement |
| Astra Zeneca Pharmaceutical | Delaware | state | 2009 | $7,195 | | training reimbursement |
| Astra Zeneca Pharmaceutical | Delaware | state | 2007 | $6,650 | | training reimbursement |
| AstraZeneca Pharmaceuticals | Delaware | state | 2016 | $5,868 | | training reimbursement |
| Alexion Pharmaceuticals | Rhode Island | state | 2013 | undisclosed | | tax credit/rebate |
